November 2021
"Target class-specific libraries mean you need to screen less to identify high-quality antibodies. Aaron Sato, Chief Scientific Officer at Twist Bioscience, elaborates.
Antibody developers are increasingly utilising antibody libraries to derive high-quality, drug-like biologics. However, only a few general-purpose libraries have been commercially available for drug discovery. As a result, most approved library-derived antibodies originate from just three libraries. The drugs also target relatively low-hanging fruit: like cytokines or tyrosine kinase receptors. To target hard-to-drug targets like G protein-coupled receptors (GPCRs), more libraries, including better and more targeted libraries, are needed."